– IOVaxis buys an exclusive option to license the TG01/02 cancer vaccines for China, Hong Kong, Macau and Singapore, for a fee of USD 250.000 – If exercised, the license has a potential value of up to USD 100 million in development and commercial...
– Duchenne UK Grants Over $600,000 in Funding to Support Patient and Clinical Trial Site Costs — BOSTON–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that...
Texas Medical Center is the largest medical complex in the world with 10 million patient encounters per year and a 1,345-acre campus (50 million square feet of developed facilities) InFoods® Diagnostic Guided Therapy (DGT) is designed to identify patient specific...
SUZHOU, China, Jan. 8, 2020 /PRNewswire/ — CStone Pharmaceuticals (“CStone” or the “Company”, HKEX: 2616) announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Company’s anti-PD-L1 antibody...
Foundational study with plans to address multiple types of agitation associated with dementia Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders Topline results expected in mid-2020 NEW HAVEN, Conn., Jan. 07, 2020 (GLOBE NEWSWIRE)...
Email
Text